Clinical trials: open to volunteers, sponsored by Janssen Research & Development, LLC
Myasthenia Gravis
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG).
- Trial name
- NCT04951622
- Testing
- Nipocalimab, Nipocalimab SC-LIV
- Where
- 112 sites in United States, Australia and 15 more
- Volunteers
- 199 people
- Sponsor
- Janssen Research & Development, LLC
Neoplasms, Advanced Solid Tumors
A Study of JNJ-87890387 for Advanced Solid Tumors
The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).
- Trial name
- NCT06178614
- Testing
- JNJ-87890387
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 200 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
The purpose of this study is to compare how well Ramantamig plus Daratumumab (ramantamig-D) works compared with a treatment that includes Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd), followed by high-dose…
- Trial name
- TRIlogy-6 (NCT07903272)
- Testing
- Ramantamig, Daratumumab, Bortezomib
- Volunteers
- 1,000 people
- Sponsor
- Janssen Research & Development, LLC
Acute Leukemia
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of bleximenib in phase 1 Part 1 (Dose Escalation) and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion).
- Trial name
- cAMeLot-1 (NCT04811560)
- Testing
- Bleximenib
- Where
- 102 sites in United States, Australia and 11 more
- Volunteers
- 420 people
- Sponsor
- Janssen Research & Development, LLC
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
The purpose of this study is to collect long-term safety data in participants with cancers including acute myeloid leukemia, non-Hodgkin lymphoma, myelodysplastic syndrome, chronic lymphocytic leukemia (type of cancer of the…
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
- Trial name
- NCT06788509
- Testing
- JNJ-75348780, JNJ-67856633, JNJ-54179060
- Where
- 39 sites in Australia, Belgium and 13 more
- Volunteers
- 120 people
- Sponsor
- Janssen Research & Development, LLC
Neoplasms
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D[s]) and optimal dosing schedule(s) of JNJ-88549968 in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968…
- Trial name
- NCT06150157
- Testing
- JNJ-88549968, Ruxolitinib, Momelotinib
- Where
- 46 sites in United States, Canada and 8 more
- Volunteers
- 300 people
- Sponsor
- Janssen Research & Development, LLC
Pregnancy Related, Pregnancy
A Study to Assess Pregnancy, Neonatal and Infant Outcomes in Participants Exposed to Nipocalimab
The purpose of this study is to find out how often: Pregnancy problems, complications in mothers, and health issues in newborn babies occurred in participants who took nipocalimab just before or during pregnancy.
- Conditions
- Pregnancy Related, Pregnancy, Pregnancy High-risk
- Trial name
- PETUNIA (NCT07915232)
- Volunteers
- 162 people
- Sponsor
- Janssen Research & Development, LLC
Myasthenia Gravis
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
The purpose of this study is to determine the effect of nipocalimab on total serum immunoglobulin G (IgG) in pediatric participants 2 to less than (<) 18 years of age (globally) and 8 to <18 years of age (for Unites Stated (US)…
- Trial name
- NCT05265273
- Testing
- Nipocalimab
- Where
- 19 sites in United States, Japan and 2 more
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
Lupus Erythematosus, Systemic
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
The purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus erythematosus (SLE, a long-term disease where the immune system mistakenly attacks…
- Trial name
- GARDENIA-SLE (NCT07438496)
- Testing
- Nipocalimab, Standard of care treatment
- Where
- 272 sites in United States, Argentina and 31 more
- Volunteers
- 600 people
- Sponsor
- Janssen Research & Development, LLC
Colorectal Neoplasms
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy…
- Trial name
- OrigAMI-3 (NCT06750094)
- Testing
- Amivantamab, Cetuximab, Bevacizumab
- Where
- 251 sites in United States, Australia and 24 more
- Volunteers
- 700 people
- Sponsor
- Janssen Research & Development, LLC
Carcinoma, Non-Small-Cell Lung
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
The purpose of this study is to assess the ability to slow down or stop the growth of cancer with amivantamab combined with either lazertinib or chemotherapy (carboplatin and pemetrexed) in participants with resectable, epidermal…
- Trial name
- AmiNA (NCT07586202)
- Testing
- Amivantamab, Lazertinib, Carboplatin
- Where
- 27 sites in United States, Canada and 4 more
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to…
- Trial name
- NCT05327114
- Testing
- Nipocalimab
- Where
- 120 sites in United States, Argentina and 17 more
- Volunteers
- 201 people
- Sponsor
- Janssen Research & Development, LLC
Colorectal Neoplasms, Gastrointestinal Neoplasms
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) and best way to take (optimal route of administration) JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in…
- Trial name
- NCT06663319
- Testing
- JNJ-89402638, Bevacizumab, FOLFOX
- Where
- 12 sites in United States, South Korea and 1 more
- Volunteers
- 260 people
- Sponsor
- Janssen Research & Development, LLC
Non-Muscle Invasive Bladder Neoplasms
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or symptoms of the cancer returning, or progressing) between Bacillus…
- Trial name
- MoonRISe-3 (NCT06919965)
- Testing
- TAR-210, Mitomycin C, Gemcitabine
- Where
- 115 sites in United States, Argentina and 13 more
- Volunteers
- 220 people
- Sponsor
- Janssen Research & Development, LLC
Advanced-stage Solid Tumors
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
The purpose of this study is to determine safe and effective dose (recommended phase 2 doses [RP2Ds]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose…
- Trial name
- NCT07223125
- Testing
- JNJ-89862175
- Where
- 7 sites in United States, France and 1 more
- Volunteers
- 360 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
The main purpose of this study is to see how well a new treatment ramantamig-D works compared to standard treatments that is either DVRd or DRd on progression-free survival (PFS; time until a participant's disease worsens) and…
- Trial name
- TRIlogy-7 (NCT07665450)
- Testing
- Ramantamig, Daratumumab, Lenalidomide
- Where
- 103 sites in Australia, Czechia and 12 more
- Volunteers
- 1,000 people
- Sponsor
- Janssen Research & Development, LLC
Asthma
A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma
The purpose of this study is to assess how well JNJ-95597528 works when compared to placebo in adult participants with moderate to severe asthma (long-term condition that affects the airways in your lungs).
- Trial name
- READY-BREATHE (NCT07746687)
- Testing
- JNJ-95597528
- Where
- 19 sites in United States, Argentina and 3 more
- Volunteers
- 440 people
- Sponsor
- Janssen Research & Development, LLC
Hematologic Neoplasms
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose [RP2D]) of JNJ-95804306.
- Trial name
- NCT07572006
- Testing
- JNJ-95804306, AML SoC, CLL/SLL SoC
- Where
- 19 sites in United States, Australia and 5 more
- Volunteers
- 320 people
- Sponsor
- Janssen Research & Development, LLC
Squamous Cell Carcinoma of Head and Neck
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants…
- Trial name
- OrigAMI-5 (NCT07276399)
- Testing
- Amivantamab, Pembrolizumab, Carboplatin
- Where
- 205 sites in United States, Australia and 20 more
- Volunteers
- 600 people
- Sponsor
- Janssen Research & Development, LLC
Crohn Disease
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe…
- Trial name
- ICONIC-CD (NCT07196722)
- Testing
- Icotrokinra
- Where
- 395 sites in United States, Argentina and 26 more
- Volunteers
- 1,092 people
- Sponsor
- Janssen Research & Development, LLC